Eleven Biotherapeutics Completes Enrollment of EBI-005 in Patients with Dry Eye Disease

Eleven Biotherapeutics (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven’s lead drug candidate in development…